TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2/26/24 19:01 | 2/23/24 | GKOS | Glaukos Corp | DE | Health | MdEq | Surgical & Medical Instrument | Foley Mark J | CA | D | S.d | -423 | 92.87 | 0 | -5 | -12 | 33 | D | |||||||||||||||
8/4/23 17:07 | 8/3/23 | RVNC | Revance Therapeutics, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Foley Mark J | TN | DO | CEO | S | -593 | 22.57 | 0 | -26 | -3 | 951 | D | ||||||||||||||
7/5/23 21:11 | 7/3/23 | RVNC | Revance Therapeutics, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Foley Mark J | TN | DO | CEO | S | -655 | 24.94 | 0 | -26 | -3 | 978 | D | ||||||||||||||
6/13/23 20:09 | 6/9/23 | RVNC | Revance Therapeutics, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Foley Mark J | TN | DO | CEO | S | -961 | 30.72 | 0 | -31 | -3 | 1,003 | D | ||||||||||||||
5/16/23 20:29 | 5/15/23 | RVNC | Revance Therapeutics, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Foley Mark J | TN | DO | CEO | S | -2,434 | 34.55 | 0 | -70 | -6 | 1,034 | D | ||||||||||||||
3/9/23 21:45 | 3/9/23 | RVNC | Revance Therapeutics, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Foley Mark J | TN | DO | CEO | S | -2,223 | 31.59 | 0 | -70 | -7 | 934 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |